

Urokinase Treated IVH Clearance Rate




Fig. 1

Effect of Urokinase on Clot Lysis

WO 03/082325

2/8

PCT/US03/09939
10/509694





Fig. 2

10/509694


Fig. 3 Protocol for Intraventricular Thrombolysis



10/509694

Fig. 4

IVH Outcomes **Safety Monitoring: Primary Endpoints** 39 Patients Enrolled



Safety Endpoint Triggers
 Deaths - > 75%
 Ventriculitis - > 30%
 Rebleeds - > 35%

% Deaths - 20.5% (8/39)
 % Ventriculitis - 7.7% (3/39)
 % Rebleeds - 23.1% (9/39)

BEST AVAILABLE COPY

Rapid Clot Lysis—IVH





Fig. 5

10/509694

Relation Between Clot Lysis and Consciousness Level

Fig. 6



Relation Between Clot Lysis and Consciousness Level

Fig. 7




Fig. 8

Predicted Probability of Death v. Actual Death in Patients Receiving Urokinase/Placebo

STUDY/PATIENT GROUP	SAMPLE SIZE	AVERAGE IVH SIZE	AVERAGE ICH SIZE	AVERAGE GCS	AVERAGE PULSE PRESSURE	PREDICTED PROBABILITY OF MORTALITY	ACTUAL PROBABILITY MORTALITY	P-VALUE FOR MORTALITY REDUCTION
PILOT UK/ALL PATIENTS	12	34.8	3.93	9	92	58.00%	25%	0.022
RANDOMIZED UK/UK PATIENTS	6	66.8	3.71	8	97	38.00%	0%	0.057
RANDOMIZED UK/PLACEBO PATIENTS	5	41.5	13.3	8	95	58.00%	20%	0.103
RANDOMIZED I-PA/ALL PATIENTS	34	53.8	4.17	8	86	77.71%	23.5%	<0.00001